The USTR Special 301 Report has been issued in the background of on-going US-India Bilateral Treaty negotiations, and has a defined diplomatic impact. Domestic patent regulation is impacted by geopolitical developments. Premature changes in patent regulation, agreed to in pressures of trade negotiations, have weakened stakeholder bargaining positions in development of generic medicines. In this blog, I examine the USTR’s repeated demands on addressal of shortcomings in Section 3(d) jurisprudence, data exclusivity and patent linkage. I situate these demands in the background of the impact that recent trade negotiations of the India-EFTA TEPA and India-UK CETA have had on the Indian patent system. I argue that any further dilution in patent law and policy is IP maximalism, will be contrary to domestic welfare schemes and sets a bad precedent for south-south policy diffusion. Instead of such dilution, access to affordable medicines needs redressal of existing jurisprudential gaps in patent enforcement; and a policy that protects domestic interests, especially now, when the US moves aggressively towards trade unilateralism on generics production.